receptor agonist (EC50
values are 780 and 555 nM at murine and human PPARγ
receptors respectively). Displays no activity at PPARα
receptors. Antidiabetic agent; exerts potent glucose-lowering effects in insulin-resistant diabetic mice. Displays anti-invasive effect on human breast cancer cells; reduces migration, adhesion and spreading on fibronectin-coated plates. Also inhibits cell growth of hematopoietic cell lines. Inhibits lamellipodia formation and actin polymerization.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Ligand type-specific interactions of peroxisome-proliferator-activated receptor γ with transcriptional coactivators.
Kodera et al.
Acute effects of troglitazone on in vivo insulin action in normal rats.
Lee and Olefsky
The PPARs: from orphan receptors to drug discovery.
Willson et al.
Effects of troglitazone on the growth and differentiation of hematopoietic cell lines.
Fujimura et al.